Viral Vector Development Service Global Market Report 2025

The viral vector development service market size has grown rapidly in recent years. It will grow from $1.77 billion in 2024 to $2.1 billion in 2025 at a compound annual growth rate (CAGR) of 18.5%. Growth during the historic period can be linked to the increasing adoption of gene therapies, rising investment in cell and gene therapy research, growing demand for viral vectors, expansion of biopharmaceutical manufacturing capacity, and heightened emphasis on viral vector quality and safety.

The viral vector development service market size is expected to see rapid growth in the next few years. It will grow to $4.09 billion in 2029 at a compound annual growth rate (CAGR) of 18.1%. Growth in the forecast period can be attributed to increasing funding for advanced therapies, a rising number of viral vector-based clinical trials, growing demand for high-purity viral vectors, expansion of contract development and manufacturing organizations, and stronger regulatory support for bioprocessing advancements. Key trends expected in the forecast period include technological progress in viral vector design, innovations in scalable viral vector production, advancements in automated purification technologies, research and development of serotype-specific viral vectors, and wider adoption of integrated manufacturing platforms.

The increasing demand for gene therapies is anticipated to drive the growth of the viral vector development service market in the near future. Gene therapies involve the introduction, removal, or alteration of genetic material within a patient’s cells to treat or prevent diseases. The rising demand for these therapies is being fueled by advancements in delivery systems, which enable the safe, efficient, and targeted delivery of genetic material into cells. Viral vector development services play a key role in supporting gene therapies by offering comprehensive solutions for the design, production, and optimization of viral vectors, making them indispensable for the development of advanced therapeutics. These services enhance treatment efficiency by ensuring targeted and safe gene delivery, thus accelerating both research and clinical applications. For example, in December 2024, the American Society of Gene & Cell Therapy (ASGCT) reported that the U.S. Food and Drug Administration (FDA) approved six gene therapy products in 2023, up from five approvals in 2022. As a result, the growing demand for gene therapies is driving the expansion of the viral vector development service market.

Key players in the viral vector development service market are focusing on innovations in biotechnological research, such as next-generation viral vector technology platforms, to improve gene delivery efficiency. These advanced systems allow for safer, more efficient, and targeted gene delivery using viral vectors, with better scalability and a reduced immune response. For instance, in November 2023, SK Pharmteco Co. Ltd., a U.S.-based contract development and manufacturing organization (CDMO), introduced new viral vector technology platforms, LentiSure and AAVelocity, to strengthen its position in the fast-growing cell and gene therapy sector. LentiSure is designed to enhance lentiviral vector production by improving transfection efficiency, scalability, and batch consistency, while AAVelocity increases adeno-associated viral (AAV) vector yields through advanced process control and purification techniques. These platforms enable more rapid, reliable, and cost-effective viral vector manufacturing, supporting next-generation therapeutic development.

In November 2023, Ajinomoto Co. Inc., a Japan-based food and biotechnology company, acquired Forge Biologics Holdings LLC for $620 million. With this acquisition, Ajinomoto Co. Inc. aims to bolster its viral vector development and manufacturing capabilities, enhancing its Bio-Pharma Services division to support the production of transformative gene therapies. Forge Biologics Holdings LLC, a U.S.-based CDMO specializing in end-to-end viral vector production for gene therapy applications, will now contribute to Ajinomoto’s efforts to advance this vital biotechnology sector.

Major companies operating in the viral vector development service market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, WuXi AppTec Co. Ltd., Catalent Inc., Charles River Laboratories International Inc., FUJIFILM Diosynth Biotechnologies Ltd., AGC Biologics Inc., GenScript Biotech Corporation, Takara Bio Inc., Oxford Biomedica plc, Cell and Gene Therapy Catapult Ltd., BioNTech IMFS GmbH, FinVector Oy, Aldevron LLC, ViroCell Biologics Ltd., Cobra Biologics Ltd., SIRION Biotech GmbH, Vigene Biosciences Inc., Creative Biogene Co. Ltd.

North America was the largest region in the viral vector development service market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in viral vector development service report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the viral vector development service market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The viral vector development service market research report is one of a series of new reports that provides viral vector development service market statistics, including viral vector development service industry global market size, regional shares, competitors with a viral vector development service market share, detailed viral vector development service market segments, market trends and opportunities, and any further data you may need to thrive in the viral vector development service industry. This viral vector development service market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Viral vector development service refers to the specialized activities involved in designing, optimizing, and producing viral vectors used in gene therapy, vaccines, and cell therapy applications. It emphasizes delivering high-quality vector development through process optimization, scalability, and adherence to regulatory standards. This service is essential for advancing research and clinical progress by helping biopharmaceutical companies efficiently bring gene-based therapies to market.

The primary vector types offered through viral vector development services include adenoviral vectors, lentiviral vectors, retroviral vectors, adeno-associated viral vectors, and others. Adenoviral vectors are engineered viral particles originating from adenoviruses and are designed to effectively deliver therapeutic genes into target cells. These services are provided through online sales, direct sales, distributors, and retailers, and are used in gene therapy, vaccine development, cancer treatment, and other applications. Major end users include pharmaceutical companies, academic and research institutions, food manufacturers, and cosmetic manufacturers.

The viral vector development service market includes revenues earned by entities through viral vector process development, viral vector analytical testing, viral vector scale-up and optimization, viral vector quality control and validation, and viral vector fill-finish and packaging services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.